BR112023019511A2 - Composto inibidor de parp7, composto, composição farmacêutica, kit farmacêutico para o tratamento de um câncer, método de tratamento de uma doença e/ou uma condição e/ou um distúrbio, e, método de síntese de um composto - Google Patents

Composto inibidor de parp7, composto, composição farmacêutica, kit farmacêutico para o tratamento de um câncer, método de tratamento de uma doença e/ou uma condição e/ou um distúrbio, e, método de síntese de um composto

Info

Publication number
BR112023019511A2
BR112023019511A2 BR112023019511A BR112023019511A BR112023019511A2 BR 112023019511 A2 BR112023019511 A2 BR 112023019511A2 BR 112023019511 A BR112023019511 A BR 112023019511A BR 112023019511 A BR112023019511 A BR 112023019511A BR 112023019511 A2 BR112023019511 A2 BR 112023019511A2
Authority
BR
Brazil
Prior art keywords
compound
treatment
independently
parp7
disorder
Prior art date
Application number
BR112023019511A
Other languages
English (en)
Inventor
Alan Wise
Michael Jordan Allan
Edward Mcguinness Barry
Kaur CHOHAN Kamaldeep
Morgan Jouanneau
Martin Cowley Phillip
Original Assignee
Duke Street Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104664.4A external-priority patent/GB202104664D0/en
Priority claimed from GBGB2114315.1A external-priority patent/GB202114315D0/en
Application filed by Duke Street Bio Ltd filed Critical Duke Street Bio Ltd
Publication of BR112023019511A2 publication Critical patent/BR112023019511A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto inibidor de parp7, composto, composição farmacêutica, kit farmacêutico para o tratamento de um câncer, método de tratamento de uma doença e/ou uma condição e/ou um distúrbio, e, método de síntese de um composto. composto compreendendo a fórmula (i), em que cada x1 é independentemente selecionado dentre c, n, o e s; cada y é independentemente selecionado dentre c e n; z1 é independentemente selecionado dentre c e n; cada x1 pode ser independentemente não substituído ou pode ser independentemente substituído com h ou um grupo orgânico substituído ou não substituído; cada y pode ser independentemente não substituído ou pode ser independentemente substituído com h ou um grupo orgânico substituído ou não substituído; m pode ser 1, 2, 3 ou 4; n pode ser 1, 2 ou 3; as ligações entre todos os átomos no anel a podem ser independentemente ligações simples ou ligações duplas; as ligações entre todos os átomos no anel b podem ser independentemente ligações simples ou ligações duplas; e em que r1 pode estar ligado a z1 por uma ligação simples ou uma ligação dupla.
BR112023019511A 2021-03-31 2022-03-30 Composto inibidor de parp7, composto, composição farmacêutica, kit farmacêutico para o tratamento de um câncer, método de tratamento de uma doença e/ou uma condição e/ou um distúrbio, e, método de síntese de um composto BR112023019511A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104664.4A GB202104664D0 (en) 2021-03-31 2021-03-31 Pharmaceutical compound
GBGB2114315.1A GB202114315D0 (en) 2021-10-06 2021-10-06 Pharmaceutical compound
PCT/EP2022/058490 WO2022207752A1 (en) 2021-03-31 2022-03-30 Pharmaceutical compound

Publications (1)

Publication Number Publication Date
BR112023019511A2 true BR112023019511A2 (pt) 2023-10-31

Family

ID=81448704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019511A BR112023019511A2 (pt) 2021-03-31 2022-03-30 Composto inibidor de parp7, composto, composição farmacêutica, kit farmacêutico para o tratamento de um câncer, método de tratamento de uma doença e/ou uma condição e/ou um distúrbio, e, método de síntese de um composto

Country Status (8)

Country Link
EP (1) EP4313300A1 (pt)
JP (1) JP2024514539A (pt)
KR (1) KR20230171440A (pt)
AU (1) AU2022249724A1 (pt)
BR (1) BR112023019511A2 (pt)
CA (1) CA3211149A1 (pt)
IL (1) IL305956A (pt)
WO (1) WO2022207752A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3202460T (pt) * 2010-02-11 2019-08-05 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
CN107074791A (zh) * 2014-07-28 2017-08-18 德累斯顿工业大学 用于抑制hsp27的胸腺嘧啶衍生物和喹唑啉二酮衍生物
NZ730475A (en) * 2014-10-29 2018-09-28 Dong A St Co Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
JP7447384B2 (ja) * 2018-06-21 2024-03-12 オスロ ウニヴェルスィテーツスィーケフース ハーエフ 方法
JP7168773B2 (ja) * 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
EP4028557A1 (en) * 2019-09-12 2022-07-20 Aurigene Discovery Technologies Limited Method for identifying responders to smarca2/4 degraders

Also Published As

Publication number Publication date
KR20230171440A (ko) 2023-12-20
IL305956A (en) 2023-11-01
WO2022207752A1 (en) 2022-10-06
CA3211149A1 (en) 2022-10-06
EP4313300A1 (en) 2024-02-07
JP2024514539A (ja) 2024-04-02
AU2022249724A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112021018303A2 (pt) Novos inibidores de pequenas moléculas de fatores de transcrição tead
ES2495743T3 (es) Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino
BRPI0507034A (pt) compostos orgánicos
BRPI0518798A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR112016022785A8 (pt) composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
BR112022018600A2 (pt) Compostos, composição farmacêutica, método de tratamento de uma doença e combinação
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
BR0010555A (pt) Inibidores de neuraminidases
BRPI0509668A (pt) composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
BR0208265A (pt) Redução estereosseletiva de acetofenona substituìda
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
BRPI0410238A (pt) compostos orgánicos
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.